Pharmaron Beijing Co., Ltd. (SHE:300759)
China · Delayed Price · Currency is CNY 36.80
+0.79 (2.19%)
Jul 31, 2026, 3:04 PM CST
Pharmaron Beijing Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 14,575 | 14,095 | 12,276 | 11,538 | 10,266 | 7,444 |
Revenue Growth | 14.73% | 14.82% | 6.39% | 12.39% | 37.92% | 45.00% |
Gross Profit Gross Profit Growth | 5,010 | 4,890 | 4,184 | 4,116 | 3,764 | 2,676 |
Operating Income Operating Income Growth | 2,073 | 2,045 | 1,719 | 1,690 | 1,667 | 1,448 |
Net Income Net Income Growth | 1,694 | 1,664 | 1,793 | 1,601 | 1,375 | 1,661 |
Earnings Per Share EPS Growth | 0.95 | 0.94 | 1.01 | 0.90 | 0.77 | 0.91 |
EPS Growth | -10.05% | -7.12% | 12.13% | 16.54% | -15.21% | 38.94% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Laboratory Services (Excl. Macromolecule and Cell and Gene Therapy Services) Laboratory Services (Excl. Macromolecule and Cell and Gene Therapy Services) Growth | 8,424 | 8,159 | 7,047 | 6,660 | - | 4,566 |
CMC (Small Molecule CDMO) Service CMC (Small Molecule CDMO) Service Growth | 3,656 | 3,483 | 2,989 | 2,711 | 2,407 | 1,746 |
Clinical Development Services Clinical Development Services Growth | 2,009 | 1,957 | 1,826 | 1,737 | 1,394 | 956.36 |
Biologics and CGT Services Biologics and CGT Services Growth | 463.83 | 474.69 | 407.52 | 424.94 | 351.03 | 150.97 |
Others Others Growth | - | 21.9 | 6.4 | 4.61 | 26.19 | 24.48 |
Total Total Growth | 14,575 | 14,095 | 12,276 | 11,538 | 10,266 | 7,444 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,977 | 2,617 | 3,062 | 6,720 | 2,856 | 6,178 |
Total Debt Total Debt Growth | 7,101 | 7,040 | 5,975 | 9,698 | 6,117 | 5,285 |
Net Cash (Debt) Net Cash Growth | -4,124 | -4,423 | -2,913 | -2,977 | -3,260 | 893.04 |
Net Cash Growth | - | - | - | - | - | -68.12% |
Net Cash Per Share Net Cash Per Share Growth | -2.31 | -2.50 | -1.64 | -1.68 | -1.84 | 0.49 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 2,973 | 3,221 | 2,577 | 2,754 | 2,143 | 2,058 |
Capital Expenditures CapEx Growth | -2,692 | -2,669 | -2,041 | -2,865 | -2,950 | -2,093 |
Free Cash Flow Free Cash Flow Growth | 280.16 | 551.97 | 536.02 | -111.78 | -807.04 | -34.78 |
Free Cash Flow Growth | -52.20% | 2.98% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Gross Margin | 34.38% | 34.70% | 34.09% | 35.67% | 36.67% | 35.95% |
Operating Margin | 14.22% | 14.51% | 14.01% | 14.64% | 16.23% | 19.45% |
Pretax Margin | 13.46% | 13.57% | 17.04% | 15.93% | 16.23% | 25.67% |
Profit Margin | 11.62% | 11.80% | 14.61% | 13.88% | 13.39% | 22.31% |
FCF Margin | 1.92% | 3.92% | 4.37% | -0.97% | -7.86% | -0.47% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.200 | 0.200 | 0.200 | 0.200 | 0.200 | 0.200 |
Dividend Per Share Growth | 0% | 0% | 0% | 0% | 0% | 50.04% |
Dividend Yield | 0.54% | 0.71% | 0.79% | 0.71% | 0.46% | 0.33% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 38.76 | 28.34 | 23.33 | 29.59 | 55.98 | 64.05 |
Forward PE | 29.68 | 24.72 | 26.22 | 25.72 | 35.75 | 59.23 |
P/FCF Ratio | 219.26 | 85.44 | 78.07 | - | - | - |
PS Ratio | 4.21 | 3.35 | 3.41 | 4.11 | 7.50 | 14.29 |